Client 1st Advisory Group
GILD icon

Client 1st Advisory Group’s Gilead Sciences GILD Stock Holding History

Client 1st Advisory Group’s Portfolio GILD Stock Details GILD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$266K Buy
1,786
+69
+4% +$9.7K 0.07% 117
2026
Q2 		$217K Buy
1,717
+117
+7% +$15.4K 0.06% 137
2026
Q1 		$223K Buy
+1,600
New +$224K 0.07% 129

Other funds holding GILD

BlackRock
BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.27T AUM 50.62% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $824B AUM 37.44% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.21T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $704B AUM 26.74% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.96T AUM 27.49% 1-Year Est. Return

Client 1st Advisory Group's GILD Position: Q3 2026 in Review

Client 1st Advisory Group increased its Gilead Sciences (GILD) stake by 4% in Q3 2026, buying an estimated $9.7K and bringing the position to 1,786 shares worth $266K. The position accounts for 0.07% of the portfolio, ranked #117.

Client 1st Advisory Group first reported a position in GILD in Q1 2026 and has held it in 3 quarters since. 2,060 funds tracked by Wall St. Rank hold GILD as of Q3 2026.

  • Client 1st Advisory Group held 1,786 shares of Gilead Sciences worth $266K as of Q3 2026.
  • Client 1st Advisory Group bought 69 Gilead Sciences shares in Q3 2026, an estimated $9.7K.
  • Gilead Sciences made up 0.07% of Client 1st Advisory Group's portfolio in Q3 2026, its #117 holding.
  • Client 1st Advisory Group first reported a position in Gilead Sciences in Q1 2026 and has held it in 3 quarters since.
  • 2,060 funds tracked by Wall St. Rank held Gilead Sciences as of Q3 2026.

Based on Client 1st Advisory Group's 13F filing for Q3 2026, filed 19 Oct 2026.